Skip to main content
    P

    ProKidney Corp. (PROK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.04
    -0.01 (-0.48%)

    Market Cap: $417.20M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    ProKidney Corp. (PROK) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to ProKidney are Precision BioSciences (DTIL), Prothena Corporation (PRTA) and DiaMedica Therapeutics (DMAC). By market cap, ProKidney ranks 4th of the 13 companies on this page; Phathom Pharmaceuticals (PHAT) is the largest at $492.63M. The median P/E of the 3 companies with a P/E is 15.0x.

    Peer Comparison

    PROK's ROIC of 21.0% is above the peer median of -20.3%, and its revenue growth of -19.8% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    ProKidney (PROK)$417.20MN/A278.8x0.0%21.0%-19.8%0.00%
    Precision BioSciences Inc (DTIL)$288.76MN/A4.4x-85.6%-38.3%37272.0%0.00%
    Prothena Corporation plc (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    DiaMedica Therapeutics Inc (DMAC)$474.29MN/AN/A0.0%N/A0.0%0.00%
    PepGen Ltd (PEPG)$410.98MN/AN/A0.0%N/A0.0%0.00%
    Rocket Pharmaceuticals Inc (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    Kyverna Therapeutics, Inc. Common Stock (KYTX)$319.27MN/AN/A0.0%-81.5%0.0%0.00%
    Phathom Pharmaceuticals Inc (PHAT)$492.63MN/A1.8x-30.2%11.4%71.1%0.00%
    Fennec Pharmaceuticals Inc (FENC)$410.25M159.5x6.8x3.0%N/A57.3%0.00%
    CorMedix Inc (CRMD)$370.64M6.3x0.9x15.5%13.9%-47.7%0.00%
    Rezolute Inc (RZLT)$353.54MN/AN/A0.0%N/A0.0%0.00%
    Korro Bio, Inc. (KRRO)$186.81MN/A175.8x0.0%-82.8%-43.1%0.00%
    Puma Biotechnology Inc (PBYI)$401.70M15.0x1.6x10.3%N/A1.1%0.00%
    Peer median$386.17M15.0x4.4x0.0%-20.3%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to ProKidney, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Precision BioSciences Inc (DTIL)
    Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States.
    DTIL competitors
    Prothena Corporation plc (PRTA)
    Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases...
    PRTA competitors
    DiaMedica Therapeutics Inc (DMAC)
    DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases.
    DMAC competitors
    PepGen Ltd (PEPG)
    PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious...
    PEPG competitors
    Rocket Pharmaceuticals Inc (RCKT)
    Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
    RCKT competitors
    Kyverna Therapeutics, Inc. Common Stock (KYTX)
    Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health...
    KYTX competitors
    Phathom Pharmaceuticals Inc (PHAT)
    Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
    PHAT competitors
    Fennec Pharmaceuticals Inc (FENC)
    Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States.
    FENC competitors
    CorMedix Inc (CRMD)
    CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious...
    CRMD competitors
    Rezolute Inc (RZLT)
    Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States.
    RZLT competitors
    Korro Bio, Inc. (KRRO)
    Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare...
    KRRO competitors
    Puma Biotechnology Inc (PBYI)
    Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States...
    PBYI competitors

    Frequently Asked Questions About PROK

    Who are ProKidney's main competitors?

    The companies most similar to ProKidney include Precision BioSciences (DTIL), Prothena Corporation (PRTA), DiaMedica Therapeutics (DMAC), PepGen (PEPG) and Rocket Pharmaceuticals (RCKT), listed from the closest match.

    Who is ProKidney's biggest competitor?

    Phathom Pharmaceuticals (PHAT) is the largest of the similar companies at $492.63M; Precision BioSciences (DTIL) is the closest match by business profile, size, sector and industry.

    How does PROK stock compare with its competitors?

    PROK's P/S is 278.8x against a peer median of 4.4x; its net margin is 0.0% against a peer median of 0.0%.

    Which of ProKidney's competitors pays a higher dividend?

    ProKidney pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is ProKidney bigger than its competitors?

    No. ProKidney is 4th by market cap among the 13 companies on this page; the largest is Phathom Pharmaceuticals (PHAT) at $492.63M.